On December 30 2020 the Oxford-AstraZeneca vaccine was approved for use in the UK. There will be more than 500,000 doses available and the vaccine is easier to store and distribute than the Pfizer-BioNTech vaccine. This will, no doubt, have an impact on the share price of the company. Investors are likely to buy shares with the hope that the share price of AstraZeneca will rise following this news and the hope that the vaccine will be approved for use in other countries worldwide.
AstraZeneca PLC (AZN) is a publicly traded drug manufacturers-general business based in the UK. It opened the day at 9935p after a previous close of 9923p. During the day the price has varied from a low of 9818p to a high of 10076p. The latest price was 10076p (25 minute delay). AstraZeneca is listed on the London Stock Exchange (LSE) and employs 83,100 staff. All prices are listed in pence sterling.
Best for
0% commission
Best for
Beginner investments
Best for
Mobile app
Best for
Referral bonus
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £0.00 £503.80 total |
Capital at risk |
|
£0 | £250 | £8.00 £511.80 total |
Capital at risk |
|
£0 | No minimum | £0.00 £503.80 total |
Capital at risk |
 |
£0 | £1 | £11.95 £515.75 total |
Capital at risk |
 |
£0 | £0.01 | £1.82 £505.62 total |
Capital at risk |
 |
£0 | £1 | £0.00 £503.80 total |
Capital at risk |
 |
£9.99 per month | No minimum | £7.99 £511.79 total |
Capital at risk |
 |
£36 per year | £20 | £9.50 £513.30 total |
Capital at risk |
Full comparison of share dealing platforms
Historical closes compared with the last close of 10076p
| 1 week (2022-09-22) | 1.43% |
|---|---|
| 1 month (2022-08-26) | -11.33% |
| 3 months (2022-06-29) | -8.85% |
| 6 months (2022-03-29) | 0.30% |
| 1 year (2021-09-28) | 18.90% |
|---|---|
| 2 years (2020-09-29) | 18.00% |
| 3 years (2019-09-27) | 36.48% |
| 5 years (2017-09-29) | 103.35% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2027. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider AstraZeneca's PEG ratio in relation to those of similar companies.
AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £12.5 billion.
The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AstraZeneca.
AstraZeneca's total ESG risk: 28.52
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AstraZeneca's overall score of 28.52 (as at 01/01/2019) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AstraZeneca is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare AstraZeneca's total ESG risk score against those of similar companies.
AstraZeneca's environmental score: 0.19/100
AstraZeneca's environmental score of 0.19 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AstraZeneca's social score: 15.45/100
AstraZeneca's social score of 15.45 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AstraZeneca's governance score: 8.88/100
AstraZeneca's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that AstraZeneca is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AstraZeneca's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, AstraZeneca scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AstraZeneca hasn't always managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
AstraZeneca PLC was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.52 |
|---|---|
| Total ESG percentile | 44.72 |
| Environmental score | 0.19 |
| Environmental score percentile | 3 |
| Social score | 15.45 |
| Social score percentile | 3 |
| Governance score | 8.88 |
| Governance score percentile | 3 |
| Level of controversy | 3 |
| Open | 9935p |
|---|---|
| High | 10076p |
| Low | 9818p |
| Close | 10076p |
| Previous close | 9923p |
| Change | 153p |
| Change % | 1.5419% |
| Volume | 2,463,414 |
| 52-week range | 8087.8553p - 11540p |
|---|---|
| 50-day moving average | 10738.96p |
| 200-day moving average | 9906.04p |
| Wall St. target price | 119.34p |
| Dividend yield | 290p (2.2%) |
| Earnings per share (TTM) | -58.8p |
Dividend yield: 2.2% of stock value
Forward annual dividend yield: 2.2% of stock value
Dividend payout ratio: 34.86% of net profits
AstraZeneca has recently paid out dividends equivalent to 2.20% of its share value annually.
AstraZeneca has paid out, on average, around 34.86% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.2% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about 290p per share.
While AstraZeneca's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 11 August 2022 (the "ex-dividend date").
AstraZeneca's dividend yield is perhaps best considered in relation to those of similar companies.
Over the last 12 months, AstraZeneca's shares have ranged in value from as little as 8087.8553p up to 11540p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while AstraZeneca's is 0.1294. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).
To put AstraZeneca's beta into context you can compare it against those of similar companies.
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ever wondered how to buy shares in Vallon Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Vallon Pharmaceuticals.
Ever wondered how to buy shares in Qualigen Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Qualigen.
